Recent update on the PPARα-null mouse

Biochimie

Volumn 79, Issue 2-3, 1997, Pages 139-144

  Gonzalez, F J ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Gene expression; Inflammatory response; Non genotoxic carcinogens; Peroxisome proliferation; PPAR

Indexed keywords

ALITRETINOIN; CELL NUCLEUS RECEPTOR; CLOFIBRATE; GEMFIBROZIL; HYPOCHOLESTEROLEMIC AGENT; MITOCHONDRIAL ENZYME; PEROXISOME PROLIFERATOR;

ARTICLE; CONTROLLED STUDY; FATTY ACID METABOLISM; INFLAMMATION; KIDNEY; LIVER; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MICROSOME; MITOCHONDRION; MOUSE; NONHUMAN; PEROXISOME; PHENOTYPE; PLEIOTROPY; REPORTER GENE; TRANSACTIVATION;

ANIMALIA; RODENTIA;

EID: 0030841938     PISSN: 03009084     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0300-9084(97)81506-4     Document Type: Article

References (34)

1. Reddy JK (1990) Carcinogenicity of peroxisome proliferators: evaluation and mechanisms. Biochem Soc Trans 18, 92-94
2. Lake BG (1995) Peroxisome proliferation: current mechanisms relating to nongenotoxic carcinogenesis. Toxicol Lett 82-83, 673-681
3. Reddy JK, Mannaerts GP (1994) Peroxisomal lipid metabolism. Annu Rev Nutr 14, 343-370
4. Lake BG (1995) Mechanisms of hepatocarcinogenicity of peroxisome-proliferating drugs and chemicals. Annu Rev Pharmacol Toxicol 35, 483-507
5. Chu S, Huang Q, Alvares K, Yeldandi AV, Rao MS, Reddy JK (1995) Transformation of mammalian cells by overexpressing H2O2-generating peroxisomal fatty acyl-CoA oxidase. Proc Natl Acad Sci USA 92, 7080-7084
6. Bayly AC, Roberts RA, Dive C (1994) Suppression of liver cell apoptosis in vitro by the non-genotoxic hepatocarcinogen and peroxisome proliferator nafenopin. J Cell Biol 125, 197-203
7. Roberts RA, Soames AR, Gill JH, James NH, Wheeldon EB (1995) Non-genotoxic hepatocarcinogens stimulate DNA synthesis and their withdrawal induces apoptosis, but in different hepatocyte populations. Carcinogenesis 16, 1693-1698
8. Green S (1995) PPAR: a mediator of peroxisome proliferator action. Mutat Res 333, 101-109
9. Schoonjans K, Staels B, Auwerx J (1996) The peroxisome proliferator activated receptors (PPARS) and their effects on lipid metabolism and adipocyte differentiation. Biochim Biophvs Acta 1302, 93-109
10. Braissant O, Foufelle F, Scotto C, Dauca M, Wahli W (1996) Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat. Endocrinology 137, 354-366
11. Tontonoz P, Graves RA, Budavari AI, Erdjument-Bromage H, Lui M, Hu E, Tempst P, Spiegelman BM (1994) Adipocyte-specific transcription factor ARF6 is a heterodimeric complex of two nuclear hormone receptors, PPAR gamma and RXR alpha. Nucleic Acids Res 22, 5628-5634
12. Tontonoz P, Hu E, Spiegelman BM (1994) Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor (published erratum appears in Cell (1995) Mar 24;80 (6): following 957). Cell 79, 1147-1156
13. Tontonoz P, Hu E, Spiegelman BM (1995) Regulation of adipocyte gene expression and differentiation by peroxisome proliferator activated receptor gamma. Curr Opin Genet Dev 5, 571-576
14. Pineau T, Hudgins WR, Liu L, Chen LC, Sher T, Gonzalez FJ, Samid D (1990) Activation of a human peroxisome proliferator-activated receptor by the antitumor agent phenylacetate and its analogs. Biochem Pharmacol 52, 659-667
15. Samid D, Shack S, Myers CE (1993) Selective growth arrest and phenotypic reversion of prostate cancer cells in vitro by non-toxic pharmacological concentrations of phenylacetate. J Clin Invest 91, 2288-2295
16. Stockhammer G, Manley GT, Johnson R, Rosenblum MK, Samid D, Lieberman FS (1995) Inhibition of proliferation and induction of differentiation in medulloblastoma- and astrocytoma-derived cell lines with phenylacetate. J Neurosurg 83, 672-681
17. Lipschutz JH, Samid D, Cunha GR (1996) Phenylacetate is an inhibitor of prostatic growth and development in organ culture. J Urol 155, 1762-1770
18. Hudgins WR, Shack S, Myers CE, Samid D (1995) Cytostatic activity of phenylacetate and derivatives against tumor cells. Correlation with lipophilicity and inhibition of protein prenylation. Biochem Pharmacol 50, 1273-1279
19. Thibault A, Samid D, Cooper MR, Figg WD, Tompkins AC, Patronas N, Headlee DJ, Kohler DR, Venzon DJ, Myers CE (1995) Phase I study of phenylacetate administered twice daily to patients with cancer. Cancer 75, 2932-2938
20. Lee SS, Pineau T, Drago J, Lee EJ, Owens JW, Kroetz DL, Fernandez-Salguero PM, Westphal H, Gonzalez FJ (1995) Targeted disruption of the alpha isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators. Mol Cell Biol 15, 3012-3022
21. Gordon GB, Helzlsouer KJ, Comstock GW (1991) Serum levels of dehydroepiandrosterone and its sulfate and the risk of developing bladder cancer. Cancer Res 51, 1366-1369
22. Shibata M, Hasegawa R, Imaida K, Hagiwara A, Ogawa K, Hirose M, Ito N, Shirai T (1995) Chemoprevention by dehydroepiandrosterone and indomethacin in a rat multiorgan carcinogenesis model. Cancer Res 55, 4870-4874
23. Shealy CN (1995) A review of dehydroepiandrosterone (DHEA). Integr Physiol Behav Sci 30, 308-313
24. Baulieu EE (1996) Dehydroepiandrosterone (DHEA): a fountain of youth? (editorial). J Clin Endocrinol Metab 81, 3147-3151
25. Clore JN (1995) Dehydroepiandrosterone and body fat. Obes Res 3 Suppl 4, 613S-616S
26. Sakuma M, Yamada J, Suga T (1993) Induction of peroxisomal beta-oxidation by structural analogues of dehydroepiandrosterone in cultured rat hepatocytes: structure-activity relationships. Biochim Biophys Acta 1169, 66-72
27. Peters JM, Zhou YC, Ram PA, Lee SS, Gonzalez FJ, Waxman DJ (1996) Peroxisome proliferator-activated receptor alpha required for gene induction by dehydroepiandrosterone-3 beta-sulfate. Mol Pharmacol 50, 67-74
28. Gottlicher M, Widmark E, Li Q, Gustafsson JA (1992) Fatty acids activate a chimera of the clofibric acid-activated receptor and the glucocorticoid receptor. Proc Natl Acad Sci USA 89, 4653-4657
29. Gearing KL, Gottlicher M, Widmark E, Banner CD, Tollet P, Stromstedt M, Rafter JJ, Berge RK, Gustafsson JA (1994) Fatty acid activation of the peroxisome proliferator activated receptor, a member of the nuclear receptor gene superfamily. J Nutr 124, 1284S-1288S
30. Yu K, Bayona W, Kallen CB, Harding HP, Ravera CP, McMahon G, Brown M, Lazar MA (1995) Differential activation of peroxisome proliferator-activated receptors by eicosanoids. J Biol Chem 270, 23975-23983
31. Devchand PR, Keller H, Peters JM, Vazquez M, Gonzalez FJ, Wahli W (1996) The PPARα leukotriene pathway to inflammation control. Nature 384, 39-43
32. Lake BG, Evans JG, Gray TJ, Korosi SA, North CJ (1989) Comparative studies on nafenopin-induced hepatic peroxisome proliferation in the rat, Syrian hamster, guinea pig, and marmoset. Toxicol Appl Pharmacol 99, 148-160
33. Lake BG, Charzat C, Tredger JM, Renwick AB, Beamand JA, Price RJ (1996) Induction of cytochrome P450 isoenzymes in cultured precision-cut rat and human liver slices. Xenobiotica. 26, 297-306
34. Sher T, Yi HF, McBride OW, Gonzalez FJ (1993) cDNA cloning, chromosomal mapping, and functional characterization of the human peroxisome proliferator activated receptor. Biochemistry 32, 5598-5604